By Rachel Lilley

On March 3, 2020, Neo Exchange Inc. (NEO) announced it had granted final approval to Mind Medicine Inc. (MindMed), a neuro-pharmaceutical company for psychedelic-inspired medicines, to make its global public markets debut. MindMed will begin trading on March 3 on the NEO Exchange under the symbol NEO:MMED, and is expected to become the world’s first publicly traded psychedelic pharmaceutical company. The company recently raised $24.2 million USD in a pre-public funding round. Investors can trade shares of NEO:MMED through their usual investment channels, including discount brokerage platforms and full-service dealers. MindMed develops medicines derived from psychedelics to address significant unmet…
Content Restricted

You must be a Free or Elite member to view this resource.

Log In | Sign up or learn more about membership options.

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!